Prolonged glucocorticoid treatment and secondary prevention in acute respiratory distress syndrome

Expert Review of Respiratory Medicine

Volumn 4, Issue 2, 2010, Pages 201-210

  Meduri, G Umberto ^a   Rocco, Patricia R M ^b   Annane, Djillali ^c   Sinclair, Scott E ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

Acute respiratory distress syndrome; Duration; Fibrosis; Glucocorticoid; Intensive care unit; Lung injury score; Mechanical ventilation; Mortality; Secondary prevention; Systematic inflammation; Treatment

Indexed keywords

CORTICOSTEROID; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; METHYLPREDNISOLONE; NEUROMUSCULAR BLOCKING AGENT;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; DISEASE SURVEILLANCE; DOWN REGULATION; DRUG RESPONSE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INFECTION; INFLAMMATION; INNATE IMMUNITY; LENGTH OF STAY; LOW DRUG DOSE; MUSCLE WEAKNESS; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; REBOUND; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION;

EID: 77951449833     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.10.2     Document Type: Review

References (70)

1. Rubenfeld GD, Caldwell E, Peabody E et al. Incidence and outcomes of acute lung injury. N. Engl. J. Med. 353, 1685-1693 (2005). (Pubitemid 41464707)
2. Angus DC, Clermont G, Linde-Zwirble WT et al. Healthcare costs and long-term outcomes after acute respiratory distress syndrome: a Phase III trial of inhaled nitric oxide. Crit. Care Med. 34, 2883-2890 (2006). (Pubitemid 44808728)
3. Meduri GU, Marik PE, Chrousos GP et al. Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med. 34, 61-69 (2008).
4. Tang B, Craig J, Eslick G, Seppelt I, McLean A. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit. Care Med. 37, 1594-1603 (2009).
5. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 138, 720-723 (1988).
6. Meduri GU, Annane D, Chrousos GP, Marik PE, Sinclair SE. Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. Chest 136, 1631-1643 (2009).
7. Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP. Nuclear factor-kB- and glucocorticoid receptor a-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation 12, 321-338 (2005).
8. Marik PE, Pastores S, Annane D et al. Clinical practice guidelines for the diagnosis and management of corticosteroid insufficiency in critical illness: recommendations of an international task force. Crit. Care Med. 36, 1937-1949 (2008).
9. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome. Evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am. J. Respir. Crit. Care Med. 165, 983-991 (2002). (Pubitemid 34774669)
10. Meduri GU, Headley S, Tolley E, Shelby M, Stentz F, Postlethwaite A. Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. Chest 108, 1315-1325 (1995).
11. Annane D, Sebille V, Bellissant E. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit. Care Med. 34, 22-30 (2006). (Pubitemid 43032376)
12. Steinberg KP, Hudson LD, Goodman RB et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N. Engl. J. Med. 354, 1671-1684 (2006).
13. Confalonieri M, Urbino R, Potena A et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am. J. Respir. Crit. Care Med. 171, 242-248 (2005).
14. Meduri GU, Golden E, Freire AX et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 131, 954-963 (2007). (Pubitemid 46608692)
15. Varpula T, Pettila V, Rintala E, Takkunen O, Valtonen V. Late steroid therapy in primary acute lung injury. Intensive Care Med. 26, 526-531 (2000). (Pubitemid 30325867)
16. Sinclair SE, Bijoy J, Golden E, Carratu P, Umberger R, Meduri GU. Interleukin-8 and soluble intercellular adhesion molecule-1 during acute respiratory distress syndrome and in response to prolonged methylprednisolone treatment. Minerva Pneumologica 45, 93-104 (2006).
17. Headley AS, Meduri GU, Tolley E, Stentz F. Infections, SIRS, and CARS during ARDS and in response to prolonged glucocorticoid treatment [Abstract]. Am. J. Respir. Crit. Care Med. 161, A378 (2000).
18. Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am. J. Respir. Crit. Care Med. 158, 1432-1441 (1998). (Pubitemid 28536602)
19. Meduri GU. An historical review of glucocorticoid treatment in sepsis. Disease pathophysiology and the design of treatment investigation. Sepsis 3, 21-38 (1999).
20. Meduri GU, Headley S, Kohler G et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1b and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107, 1062-1073 (1995).
21. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 108, 1303-1314 (1995).
22. Meduri GU, Headley S, Golden E et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. A randomized controlled trial. JAMA 280, 159-165 (1998). (Pubitemid 28498389)
23. Leatherman JW, Fluegel WL, David WS, Davies SF, Iber C. Muscle weakness in mechanically ventilated patients with severe asthma. Am. J. Respir. Crit. Care Med. 153, 1686-1690 (1996). (Pubitemid 26141357)
24. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 105, 244-252 (2006). (Pubitemid 44148168)
25. Weber-Carstens S, Keh D. Bolus or continuous hydrocortisone - that is the question. Crit. Care 11, 113 (2007).
26. Loisa P, Parviainen I, Tenhunen J, Hovilehto S, Ruokonen E. Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: a prospective randomized trial. Crit. Care 11, R21 (2007).
27. Meduri GU, Mauldin GL, Wunderink RG et al. Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia. Chest 106, 221-235 (1994).
28. Hesterberg TW, Last JA. Ozone-induced acute pulmonary fibrosis in rats. Prevention of increased rates of collagen synthesis by methylprednisolone. Am. Rev. Respir. Dis. 123, 47-52 (1981).
29. Hakkinen PJ, Schmoyer RL, Witschi HP. Potentiation of butylated-hydroxytoluene-induced acute lung damage by oxygen. Effects of prednisolone and indomethacin. Am. Rev. Respir. Dis. 128, 648-651 (1983).
30. Kehrer JP, Klein-Szanto AJ, Sorensen EM, Pearlman R, Rosner MH. Enhanced acute lung damage following corticosteroid treatment. Am. Rev. Respir. Dis. 130, 256-261 (1984).
31. Ashbaugh DG, Maier RV. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome. Diagnosis and treatment. Arch. Surg. 120, 530-535 (1985). (Pubitemid 15053407)
32. Hooper RG, Kearl RA. Established ARDS treated with a sustained course of adrenocortical steroids. Chest 97, 138-143 (1990). (Pubitemid 20023507)
33. Briegel J, Jochum M, Gippner-Steppert C, Thiel M. Immunomodulation in septic shock: hydrocortisone differentially regulates cytokine responses. J. Am. Soc. Nephrol. 12(Suppl. 17), S70-S74 (2001). (Pubitemid 32119058)
34. Keh D, Boehnke T, Weber-Cartens S et al. Immunologic and hemodynamic effects of 'low-dose' hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am. J. Respir. Crit. Care Med. 167, 512-520 (2003).
35. Nawab Q, Golden E, Confalonieri M, Umberger R, Meduri G. Glucocorticoid treatment in severe community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 175, A594 (2007).
36. Barber AE, Coyle SM, Fischer E et al. Influence of hypercortisolemia on soluble tumor necrosis factor receptor II and interleukin-1 receptor antagonist responses to endotoxin in human beings. Surgery 118, 406-410 (1995).
37. Broug-Holub E, Kraal G. Dose- and time-dependent activation of rat alveolar macrophages by glucocorticoids. Clin. Exp. Immunol. 104, 332-336 (1996). (Pubitemid 26139780)
38. Fantuzzi G, Demitri MT, Ghezzi P. Differential effect of glucocorticoids on tumour necrosis factor production in mice: up-regulation by early pretreatment with dexamethasone. Clin. Exp. Immunol. 96, 166-169 (1994). (Pubitemid 24213815)
39. Barber AE, Coyle SM, Marano MA et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J. Immunol. 150, 1999-2006 (1993).
40. Schaaf MJ, Cidlowski JA. Molecular mechanisms of glucocorticoid action and resistance. J. Steroid Biochem. Mol. Biol. 83, 37-48 (2002). (Pubitemid 37040640)
41. Cooper MS, Stewart PM. Adrenal insufficiency in critical illness. J. Intensive Care Med. 22, 348-362 (2007).
42. Pustavoitau A, Stevens RD. Mechanisms of neurologic failure in critical illness. Crit. Care Clin. 24, 1-24, vii (2008).
43. Headley AS, Tolley E, Meduri GU. Infections and the inflammatory response in acute respiratory distress syndrome. Chest 111, 1306-1321 (1997). (Pubitemid 27200090)
44. Meduri GU. Clinical review: a paradigm shift: the bidirectional effect of inflammation on bacterial growth. Clinical implications for patients with acute respiratory distress syndrome. Crit. Care 6, 24-29 (2002).
45. Weigelt JA, Norcross JF, Borman KR, Snyder WHD. Early steroid therapy for respiratory failure. Arch. Surg. 120, 536-540 (1985).
46. Bernard GR, Luce JM, Sprung CL et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N. Engl. J. Med. 317, 1565-1570 (1987).
47. Kaufmann I, Briegel J, Schliephake F et al. Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions. Intensive Care Med. 34, 344-349 (2008).
48. Meduri GU, Kanangat S, Bronze MS et al. Effects of methylprednisolone on intracellular bacterial growth. Clin. Diagn. Lab. Immunol. 8, 1156-1163 (2001).
49. Sibila O, Luna C, Agustí C et al. Effects of corticosteroids an animal model of ventilator-associated pneumonia. Proc. Am. Thorac. Soc. 3, A21 (2006).
50. Stevens RD, Dowdy DW, Michaels RK et al. Neuromuscular dysfunction acquired in critical illness: a systematic review. Intensive Care Med. 33, 1876-1891 (2007).
51. Hough CL, Steinberg KP, Thompson BT, Rubenfeld GD, Hudson LD. Intensive care unit-acquired neuromyopathy and corticosteroids in survivors of persistent ARDS. Intensive Care Med. 35, 63-68 (2009).
52. De Jonghe B, Bastuji-Garin S, Sharshar T, Outin H, Brochard L. Does ICU-acquired paresis lengthen weaning from mechanical ventilation? Intensive Care Med. 30, 1117-1121 (2004).
53. Fernandes AB, Zin WA, Rocco PR. Corticosteroids in acute respiratory distress syndrome. Braz. J. Med. Biol. Res. 38, 147-159 (2005).
54. Pelosi P, Rocco PR. Glucocorticoid treatment in acute respiratory distress syndrome: friend or foe? In: Yearbook of Intensive Care and Emengency Medicine. Vincent J (Ed.). Springer, Berlin, Germany, 214-223 (2008).
55. Silva PL, Garcia CS, Maronas PA et al. Early short-term versus prolonged low-dose methylprednisolone therapy in acute lung injury. Eur. Respir. J. 33, 634-645 (2009).
56. Leite-Junior JH, Garcia CS, Souza- Fernandes AB et al. Methylprednisolone improves lung mechanics and reduces the inflammatory response in pulmonary but not in extrapulmonary mild acute lung injury in mice. Crit. Care Med. 36, 2621-2628 (2008).
57. Lee HS, Lee JM, Kim MS, Kim HY, Hwangbo B, Zo JI. Low-dose steroid therapy at an early phase of postoperative acute respiratory distress syndrome. Ann. Thorac. Surg. 79, 405-410 (2005).
58. Keel JB, Hauser M, Stocker R, Baumann PC, Speich R. Established acute respiratory distress syndrome: benefit of corticosteroid rescue therapy. Respiration 65, 258-264 (1998).
59. Huh J, Lim C, Jegal Y et al. The effect of steroid therapy in patients with late ARDS. Tuberc. Respir. Dis. 52, 376-384 (2002).
60. Brower G, Matthay M. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N. Engl. J. Med. 342, 1301-1308 (2000).
61. Wiedemann HP, Wheeler AP, Bernard GR et al. Comparison of two fluid-management strategies in acute lung injury. N. Engl. J. Med. 354, 2564-2575 (2006).
62. Meduri GU. There is no illumination in speculation. Additional data in support of methylprednisolone treatment in ARDS. Chest 132(3), 1097-1100 (2007).
63. Thompson BT, Ancukiewicz M, Hudson LD, Steinberg KP, Bernard GR. Steroid treatment for persistent ARDS: a word of caution. Crit. Care 11, 425 (2007).
64. Foster JR. Steroids for early acute respiratory distress syndrome: critical appraisal of Meduri GU, Golden E, Freire AX et al.: Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007; 131:954-963. Pediatr. Crit. Care Med. DOI10.1097/ PCC.0b013e3181c014eb (2009) (Epub ahead of print).
65. Cuthbertson BH, Sprung CL, Annane D et al. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med. 35, 1868-1876 (2009).
66. Quispe-Laime AM, Bracco JD, Barberio PA et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med. 36(1), 33-41 (2010).
67. Blanco-Colio LM, Tunon J, Martin- Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 63, 12-23 (2003).
68. Plenge JK, Hernandez TL, Weil KM et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106, 1447-1452 (2002).
69. Schelling G, Briegel J, Roozendaal B, Stoll C, Rothenhausler HB, Kapfhammer HP. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol. Psychiatry 50, 978-985 (2001).
70. Schelling G, Kilger E, Roozendaal B et al. Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study. Biol. Psychiatry 55, 627-633 (2004).